New Publication: Safety and exploratory efficacy of a novel anti-C5 recycling monoclonal antibody vs standard of care in C5 inhibitor-experienced people with PNH. View the primary analysis of the Phase 3 COMMODORE 1 trial. #hematology #raredisease #thrombosis https://lnkd.in/gGpuVJhw
About us
The official Genentech Medical LinkedIn page for sharing the latest scientific, medical, and clinical trial information with US healthcare professionals. • By interacting with this LinkedIn page, you confirm that you are a US healthcare professional. • There are regulations that govern our LinkedIn page. We reserve the right to engage with posts that follow our community guidelines (https://bit.ly/4aqwv2h). Not all posts will receive responses. Responses will be provided during business hours M-F, 5am to 5pm PT. • This page provides a platform for Genentech Medical Affairs to share scientific information, disease education, and clinical trial updates. We welcome your comments. Please stay on topic and refrain from using inappropriate language. • If you are aware of anyone that has experienced any adverse events related to a Genentech product, report them immediately to Genentech Drug Safety by emailing [email protected] or calling 1-888-835-2555. You can also contact the FDA directly by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. We will report this adverse event to the FDA and may contact you with questions or request additional information. • Respect others’ privacy and do not share personal information that is not in the public domain. • Do not reference Genentech products and services or alternative therapeutic options or your posts may be deleted. • This page is for informational purposes only and is not a forum to solicit or give medical advice. • The sharing of content or links to third-party sites is not an indication of endorsement by Genentech and Genentech is not responsible for this content. • If you have a medical inquiry, contact our Medical Information team M-F, 5am to 5pm PT by calling 1-800-821-8590.
- Website
-
https://www.genentech-medinfo.com/
External link for Genentech Medical
- Industry
- Biotechnology Research
- Company size
- 10,001 employees
Updates
-
Do you have eligible patients with primary IgA nephropathy? They can participate in IMAgINATION, an ongoing clinical trial with an investigational treatment. Genentech is recruiting eligible patients across many locations nationwide. #clinicaltrial #kidneyresearch #nephrology Find a trial site near you and your patients at https://lnkd.in/gcHPAEE7
-
Primary IgA nephropathy poses a significant risk of kidney disease progression leading to kidney failure with no curative treatment available. The IMAgINATION clinical trial is evaluating the efficacy and safety of a novel therapy for patients with primary IgA nephropathy. #clinicaltrial #kidneyresearch #nephrology You can support the clinical trial by enrolling eligible patients into the IMAgINATION study at https://lnkd.in/gQmNsBu8
-
Thank you for joining us at #EHA2024. View our #hematology research by visiting MEDICALLY, our online platform for scientific exchange, congress information, and resources. https://lnkd.in/g4M6yBXB
-
-
Do you have eligible patients with untreated, unresectable locally advanced or metastatic hepatocellular carcinoma? They can participate in IMbrave152, an ongoing Phase III clinical trial of an investigational combination treatment. Trial locations are available nationwide. #LiverCancer #HepatocellularCarcinoma #HCCresearch https://lnkd.in/gHuQycpQ
-
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. In 2023, just over 40,000 Americans were estimated to have been diagnosed with liver cancer. You can support an ongoing study evaluating an investigational combination treatment regimen by enrolling eligible patients with untreated, unresectable locally advanced or metastatic HCC in the IMbrave152 clinical trial. #LiverCancer #CancerResearch #ClinicalTrial #HCCresearch https://lnkd.in/gXpa2pj5
-
Genentech is presenting abstracts at #EHA2024, showcasing some of the latest advancements in #hematology research and treatment. Join us in our commitment to advancing science and improving #patientoutcomes at our sessions for updates. https://lnkd.in/gTpkWXKD
-
Join Genentech at #EHA2024 for updated analyses from our research in #hematology across the abstract presentation sessions. Visit Genentech at booth #F02 to talk with our Medical Affairs team. https://lnkd.in/gTpkWXKD
-
Discover valuable insights on cytokine release syndrome (CRS) from Genentech. Learn how CRS manifests, recognize its key signs and symptoms, and explore considerations to support your diagnoses. Build upon your understanding by learning about the CRS grading system using the ASTCT criteria and recommendations. #CRS #Cancer https://lnkd.in/gGt5bsWW
-
Thank you for joining us at #ASCO24. For meeting attendees, you can view #oncology research by visiting MEDICALLY, our online platform for scientific exchange, congress information, and resources. https://lnkd.in/gau94Vvm
-